# A Safety and Tolerability Study of AG-519 in Healthy Subjects

> **NCT02630927** · PHASE1 · TERMINATED · sponsor: **Agios Pharmaceuticals, Inc.** · enrollment: 108 (actual)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** AG-519
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02630927
- **Lead sponsor:** Agios Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 108 (ACTUAL)
- **Why stopped:** Agios is no longer developing its second pyruvate kinase-R (PKR) activator, AG-519, and withdrew its investigational new drug (IND) application in December 2016
- **Last updated:** 2017-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02630927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02630927, "A Safety and Tolerability Study of AG-519 in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02630927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*